Expression screening of cancer/testis genes in prostate cancer identifies nr6a1 as a novel marker of disease progression and aggressiveness
Identifieur interne : 000E64 ( Istex/Corpus ); précédent : 000E63; suivant : 000E65Expression screening of cancer/testis genes in prostate cancer identifies nr6a1 as a novel marker of disease progression and aggressiveness
Auteurs : Romain Mathieu ; Bertrand Evrard ; Gaëlle Fromont ; Nathalie Rioux-Leclercq ; Julie Godet ; Xavier Cathelineau ; François Guillé ; Michael Primig ; Frédéric ChalmelSource :
- The Prostate [ 0270-4137 ] ; 2013-07.
English descriptors
- KwdEn :
Abstract
Cancer/Testis (CT) genes are expressed in male gonads, repressed in most healthy somatic tissues and de‐repressed in various somatic malignancies including prostate cancers (PCa). Because of their specific expression signature and their associations with tumor aggressiveness and poor outcomes, CT genes are considered to be useful biomarkers and they are also targets for the development of new anti‐cancer immunotherapies. The aim of this study was to identify novel CT genes associated with hormone‐sensitive prostate cancer (HSPC), and castration‐resistant prostate cancer (CRPC).
Url:
DOI: 10.1002/pros.22659
Links to Exploration step
ISTEX:6636028DAD7073A903B1AA8F93CFB8DD8ED432B5Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Expression screening of cancer/testis genes in prostate cancer identifies nr6a1 as a novel marker of disease progression and aggressiveness</title><author><name sortKey="Mathieu, Romain" sort="Mathieu, Romain" uniqKey="Mathieu R" first="Romain" last="Mathieu">Romain Mathieu</name><affiliation><mods:affiliation>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Département d'Urologie, CHU de Rennes, Rennes, France</mods:affiliation></affiliation></author><author><name sortKey="Evrard, Bertrand" sort="Evrard, Bertrand" uniqKey="Evrard B" first="Bertrand" last="Evrard">Bertrand Evrard</name><affiliation><mods:affiliation>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes, France</mods:affiliation></affiliation></author><author><name sortKey="Fromont, Gaelle" sort="Fromont, Gaelle" uniqKey="Fromont G" first="Gaëlle" last="Fromont">Gaëlle Fromont</name><affiliation><mods:affiliation>Département d'Anatomocytopathologie, CHU/Université de Poitiers, Poitiers, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Centre d'étude et de Recherche sur les Pathologies Prostatiques, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Rioux Eclercq, Nathalie" sort="Rioux Eclercq, Nathalie" uniqKey="Rioux Eclercq N" first="Nathalie" last="Rioux-Leclercq">Nathalie Rioux-Leclercq</name><affiliation><mods:affiliation>Service d'Anatomie et Cytologie Pathologiques, CHU/Université de Rennes, Rennes, France</mods:affiliation></affiliation></author><author><name sortKey="Godet, Julie" sort="Godet, Julie" uniqKey="Godet J" first="Julie" last="Godet">Julie Godet</name><affiliation><mods:affiliation>Département d'Anatomocytopathologie, CHU/Université de Poitiers, Poitiers, France</mods:affiliation></affiliation></author><author><name sortKey="Cathelineau, Xavier" sort="Cathelineau, Xavier" uniqKey="Cathelineau X" first="Xavier" last="Cathelineau">Xavier Cathelineau</name><affiliation><mods:affiliation>Institut Mutualiste Montsouris, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Guille, Francois" sort="Guille, Francois" uniqKey="Guille F" first="François" last="Guillé">François Guillé</name><affiliation><mods:affiliation>Département d'Urologie, CHU de Rennes, Rennes, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Centre Régional de Lutte Contre le Cancer Eugène Marquis, Rennes, France</mods:affiliation></affiliation></author><author><name sortKey="Primig, Michael" sort="Primig, Michael" uniqKey="Primig M" first="Michael" last="Primig">Michael Primig</name><affiliation><mods:affiliation>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes, France</mods:affiliation></affiliation></author><author><name sortKey="Chalmel, Frederic" sort="Chalmel, Frederic" uniqKey="Chalmel F" first="Frédéric" last="Chalmel">Frédéric Chalmel</name><affiliation><mods:affiliation>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes F‐35042, France.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6636028DAD7073A903B1AA8F93CFB8DD8ED432B5</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1002/pros.22659</idno><idno type="url">https://api.istex.fr/document/6636028DAD7073A903B1AA8F93CFB8DD8ED432B5/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000E64</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000E64</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Expression screening of cancer/testis genes in prostate cancer identifies nr6a1 as a novel marker of disease progression and aggressiveness</title><author><name sortKey="Mathieu, Romain" sort="Mathieu, Romain" uniqKey="Mathieu R" first="Romain" last="Mathieu">Romain Mathieu</name><affiliation><mods:affiliation>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Département d'Urologie, CHU de Rennes, Rennes, France</mods:affiliation></affiliation></author><author><name sortKey="Evrard, Bertrand" sort="Evrard, Bertrand" uniqKey="Evrard B" first="Bertrand" last="Evrard">Bertrand Evrard</name><affiliation><mods:affiliation>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes, France</mods:affiliation></affiliation></author><author><name sortKey="Fromont, Gaelle" sort="Fromont, Gaelle" uniqKey="Fromont G" first="Gaëlle" last="Fromont">Gaëlle Fromont</name><affiliation><mods:affiliation>Département d'Anatomocytopathologie, CHU/Université de Poitiers, Poitiers, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Centre d'étude et de Recherche sur les Pathologies Prostatiques, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Rioux Eclercq, Nathalie" sort="Rioux Eclercq, Nathalie" uniqKey="Rioux Eclercq N" first="Nathalie" last="Rioux-Leclercq">Nathalie Rioux-Leclercq</name><affiliation><mods:affiliation>Service d'Anatomie et Cytologie Pathologiques, CHU/Université de Rennes, Rennes, France</mods:affiliation></affiliation></author><author><name sortKey="Godet, Julie" sort="Godet, Julie" uniqKey="Godet J" first="Julie" last="Godet">Julie Godet</name><affiliation><mods:affiliation>Département d'Anatomocytopathologie, CHU/Université de Poitiers, Poitiers, France</mods:affiliation></affiliation></author><author><name sortKey="Cathelineau, Xavier" sort="Cathelineau, Xavier" uniqKey="Cathelineau X" first="Xavier" last="Cathelineau">Xavier Cathelineau</name><affiliation><mods:affiliation>Institut Mutualiste Montsouris, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Guille, Francois" sort="Guille, Francois" uniqKey="Guille F" first="François" last="Guillé">François Guillé</name><affiliation><mods:affiliation>Département d'Urologie, CHU de Rennes, Rennes, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Centre Régional de Lutte Contre le Cancer Eugène Marquis, Rennes, France</mods:affiliation></affiliation></author><author><name sortKey="Primig, Michael" sort="Primig, Michael" uniqKey="Primig M" first="Michael" last="Primig">Michael Primig</name><affiliation><mods:affiliation>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes, France</mods:affiliation></affiliation></author><author><name sortKey="Chalmel, Frederic" sort="Chalmel, Frederic" uniqKey="Chalmel F" first="Frédéric" last="Chalmel">Frédéric Chalmel</name><affiliation><mods:affiliation>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes F‐35042, France.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">The Prostate</title><title level="j" type="abbrev">Prostate</title><idno type="ISSN">0270-4137</idno><idno type="eISSN">1097-0045</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2013-07">2013-07</date><biblScope unit="volume">73</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1103">1103</biblScope><biblScope unit="page" to="1114">1114</biblScope></imprint><idno type="ISSN">0270-4137</idno></series><idno type="istex">6636028DAD7073A903B1AA8F93CFB8DD8ED432B5</idno><idno type="DOI">10.1002/pros.22659</idno><idno type="ArticleID">PROS22659</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0270-4137</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cancer/Testis genes</term><term>NR6A1</term><term>biomarker</term><term>castration‐resistant prostate cancer</term><term>nuclear receptor</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Cancer/Testis (CT) genes are expressed in male gonads, repressed in most healthy somatic tissues and de‐repressed in various somatic malignancies including prostate cancers (PCa). Because of their specific expression signature and their associations with tumor aggressiveness and poor outcomes, CT genes are considered to be useful biomarkers and they are also targets for the development of new anti‐cancer immunotherapies. The aim of this study was to identify novel CT genes associated with hormone‐sensitive prostate cancer (HSPC), and castration‐resistant prostate cancer (CRPC).</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Romain Mathieu</name><affiliations><json:string>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes, France</json:string><json:string>Département d'Urologie, CHU de Rennes, Rennes, France</json:string></affiliations></json:item><json:item><name>Bertrand Evrard</name><affiliations><json:string>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes, France</json:string></affiliations></json:item><json:item><name>Gaëlle Fromont</name><affiliations><json:string>Département d'Anatomocytopathologie, CHU/Université de Poitiers, Poitiers, France</json:string><json:string>Centre d'étude et de Recherche sur les Pathologies Prostatiques, Paris, France</json:string></affiliations></json:item><json:item><name>Nathalie Rioux‐Leclercq</name><affiliations><json:string>Service d'Anatomie et Cytologie Pathologiques, CHU/Université de Rennes, Rennes, France</json:string></affiliations></json:item><json:item><name>Julie Godet</name><affiliations><json:string>Département d'Anatomocytopathologie, CHU/Université de Poitiers, Poitiers, France</json:string></affiliations></json:item><json:item><name>Xavier Cathelineau</name><affiliations><json:string>Institut Mutualiste Montsouris, Paris, France</json:string></affiliations></json:item><json:item><name>François Guillé</name><affiliations><json:string>Département d'Urologie, CHU de Rennes, Rennes, France</json:string><json:string>Centre Régional de Lutte Contre le Cancer Eugène Marquis, Rennes, France</json:string></affiliations></json:item><json:item><name>Michael Primig</name><affiliations><json:string>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes, France</json:string></affiliations></json:item><json:item><name>Frédéric Chalmel</name><affiliations><json:string>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes, France</json:string><json:string>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes F‐35042, France.</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Cancer/Testis genes</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>castration‐resistant prostate cancer</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>biomarker</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>NR6A1</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>nuclear receptor</value></json:item></subject><articleId><json:string>PROS22659</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><qualityIndicators><score>5.972</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>584</abstractCharCount><pdfWordCount>6826</pdfWordCount><pdfCharCount>45421</pdfCharCount><pdfPageCount>12</pdfPageCount><abstractWordCount>81</abstractWordCount></qualityIndicators><title>Expression screening of cancer/testis genes in prostate cancer identifies nr6a1 as a novel marker of disease progression and aggressiveness</title><refBibs><json:item><author><json:item><name>J Ferlay</name></json:item><json:item><name>DM Parkin</name></json:item><json:item><name>E Steliarova‐Foucher</name></json:item></author><host><volume>46</volume><pages><last>781</last><first>765</first></pages><issue>4</issue><author></author><title>Eur J Cancer</title></host><title>Estimates of cancer incidence and mortality in Europe in 2008</title></json:item><json:item><author><json:item><name>A Jemal</name></json:item><json:item><name>R Siegel</name></json:item><json:item><name>E Ward</name></json:item><json:item><name>Y Hao</name></json:item><json:item><name>J Xu</name></json:item><json:item><name>MJ Thun</name></json:item></author><host><volume>59</volume><pages><last>249</last><first>225</first></pages><issue>4</issue><author></author><title>CA Cancer J Clin</title></host><title>Cancer statistics, 2009</title></json:item><json:item><author><json:item><name>KA Roehl</name></json:item><json:item><name>M Han</name></json:item><json:item><name>CG Ramos</name></json:item><json:item><name>JA Antenor</name></json:item><json:item><name>WJ Catalona</name></json:item></author><host><volume>172</volume><pages><last>914</last><first>910</first></pages><issue>3</issue><author></author><title>J Urol</title></host><title>Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long‐term results</title></json:item><json:item><author><json:item><name>JE Johansson</name></json:item><json:item><name>O Andren</name></json:item><json:item><name>SO Andersson</name></json:item><json:item><name>PW Dickman</name></json:item><json:item><name>L Holmberg</name></json:item><json:item><name>A Magnuson</name></json:item><json:item><name>HO Adami</name></json:item></author><host><volume>291</volume><pages><last>2719</last><first>2713</first></pages><issue>22</issue><author></author><title>JAMA</title></host><title>Natural history of early, localized prostate cancer</title></json:item><json:item><author><json:item><name>N Sharifi</name></json:item><json:item><name>JL Gulley</name></json:item><json:item><name>WL Dahut</name></json:item></author><host><volume>294</volume><pages><last>244</last><first>238</first></pages><issue>2</issue><author></author><title>JAMA</title></host><title>Androgen deprivation therapy for prostate cancer</title></json:item><json:item><author><json:item><name>B Xu</name></json:item><json:item><name>N Wang</name></json:item><json:item><name>X Wang</name></json:item><json:item><name>N Tong</name></json:item><json:item><name>N Shao</name></json:item><json:item><name>J Tao</name></json:item><json:item><name>P Li</name></json:item><json:item><name>X Niu</name></json:item><json:item><name>N Feng</name></json:item><json:item><name>L Zhang</name></json:item><json:item><name>L Hua</name></json:item><json:item><name>Z Wang</name></json:item><json:item><name>M Chen</name></json:item></author><host><volume>72</volume><pages><last>1178</last><first>1171</first></pages><issue>11</issue><author></author><title>Prostate</title></host><title>MiR‐146a suppresses tumor growth and progression by targeting EGFR pathway and in a p‐ERK‐dependent manner in castration‐resistant prostate cancer</title></json:item><json:item><author><json:item><name>P van der Bruggen</name></json:item><json:item><name>C Traversari</name></json:item><json:item><name>P Chomez</name></json:item><json:item><name>C Lurquin</name></json:item><json:item><name>E De Plaen</name></json:item><json:item><name>B Van den Eynde</name></json:item><json:item><name>A Knuth</name></json:item><json:item><name>T Boon</name></json:item></author><host><volume>254</volume><pages><last>1647</last><first>1643</first></pages><issue>5038</issue><author></author><title>Science</title></host><title>A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma</title></json:item><json:item><author><json:item><name>E Fratta</name></json:item><json:item><name>S Coral</name></json:item><json:item><name>A Covre</name></json:item><json:item><name>G Parisi</name></json:item><json:item><name>F Colizzi</name></json:item><json:item><name>R Danielli</name></json:item><json:item><name>HJ Marie Nicolay</name></json:item><json:item><name>L Sigalotti</name></json:item><json:item><name>M Maio</name></json:item></author><host><volume>5</volume><pages><last>182</last><first>164</first></pages><issue>2</issue><author></author><title>Mol Oncol</title></host><title>The biology of cancer testis antigens: Putative function, regulation and therapeutic potential</title></json:item><json:item><author><json:item><name>LG Almeida</name></json:item><json:item><name>NJ Sakabe</name></json:item><json:item><name>AR deOliveira</name></json:item><json:item><name>MC Silva</name></json:item><json:item><name>AS Mundstein</name></json:item><json:item><name>T Cohen</name></json:item><json:item><name>YT Chen</name></json:item><json:item><name>R Chua</name></json:item><json:item><name>S Gurung</name></json:item><json:item><name>S Gnjatic</name></json:item></author><host><volume>37</volume><pages><last>819</last><first>816</first></pages><issue>database issue</issue><author></author><title>Nucleic Acids Res</title></host><title>CTdatabase: A knowledge‐base of high‐throughput and curated data on cancer‐testis antigens</title></json:item><json:item><author><json:item><name>P Tyagi</name></json:item><json:item><name>B Mirakhur</name></json:item></author><host><volume>10</volume><pages><last>374</last><first>371</first></pages><issue>5</issue><author></author><title>Clin Lung Cancer</title></host><title>MAGRIT: The largest‐ever phase III lung cancer trial aims to establish a novel tumor‐specific approach to therapy</title></json:item><json:item><author><json:item><name>D Atanackovic</name></json:item><json:item><name>NK Altorki</name></json:item><json:item><name>Y Cao</name></json:item><json:item><name>E Ritter</name></json:item><json:item><name>CA Ferrara</name></json:item><json:item><name>G Ritter</name></json:item><json:item><name>EW Hoffman</name></json:item><json:item><name>C Bokemeyer</name></json:item><json:item><name>LJ Old</name></json:item><json:item><name>S Gnjatic</name></json:item></author><host><volume>105</volume><pages><last>1655</last><first>1650</first></pages><issue>5</issue><author></author><title>Proc Natl Acad Sci USA</title></host><title>Booster vaccination of cancer patients with MAGE‐A3 protein reveals long‐term immunological memory or tolerance depending on priming</title></json:item><json:item><author><json:item><name>OL Caballero</name></json:item><json:item><name>YT Chen</name></json:item></author><host><volume>100</volume><pages><last>2021</last><first>2014</first></pages><issue>11</issue><author></author><title>Cancer Sci</title></host><title>Cancer/Testis (CT) antigens: Potential targets for immunotherapy</title></json:item><json:item><author><json:item><name>AJ Simpson</name></json:item><json:item><name>OL Caballero</name></json:item><json:item><name>A Jungbluth</name></json:item><json:item><name>YT Chen</name></json:item><json:item><name>LJ Old</name></json:item></author><host><volume>5</volume><pages><last>625</last><first>615</first></pages><issue>8</issue><author></author><title>Nat Rev Cancer</title></host><title>Cancer/Testis antigens, gametogenesis and cancer</title></json:item><json:item><author><json:item><name>VC Andrade</name></json:item><json:item><name>AL Vettore</name></json:item><json:item><name>RS Felix</name></json:item><json:item><name>MS Almeida</name></json:item><json:item><name>F Carvalho</name></json:item><json:item><name>JS Oliveira</name></json:item><json:item><name>ML Chauffaille</name></json:item><json:item><name>A Andriolo</name></json:item><json:item><name>OL Caballero</name></json:item><json:item><name>MA Zago</name></json:item></author><host><volume>8</volume><pages><first>2</first></pages><author></author><title>Cancer Immun</title></host><title>Prognostic impact of Cancer/Testis antigen expression in advanced stage multiple myeloma patients</title></json:item><json:item><author><json:item><name>A Grigoriadis</name></json:item><json:item><name>OL Caballero</name></json:item><json:item><name>KS Hoek</name></json:item><json:item><name>L da Silva</name></json:item><json:item><name>YT Chen</name></json:item><json:item><name>SJ Shin</name></json:item><json:item><name>AA Jungbluth</name></json:item><json:item><name>LD Miller</name></json:item><json:item><name>D Clouston</name></json:item><json:item><name>J Cebon</name></json:item></author><host><volume>106</volume><pages><last>13498</last><first>13493</first></pages><issue>32</issue><author></author><title>Proc Natl Acad Sci USA</title></host><title>CT‐X antigen expression in human breast cancer</title></json:item><json:item><author><json:item><name>AO Gure</name></json:item><json:item><name>R Chua</name></json:item><json:item><name>B Williamson</name></json:item><json:item><name>M Gonen</name></json:item><json:item><name>CA Ferrera</name></json:item><json:item><name>S Gnjatic</name></json:item><json:item><name>G Ritter</name></json:item><json:item><name>AJ Simpson</name></json:item><json:item><name>YT Chen</name></json:item><json:item><name>LJ Old</name></json:item></author><host><volume>11</volume><pages><last>8062</last><first>8055</first></pages><issue>22</issue><author></author><title>Clin Cancer Res</title></host><title>Cancer‐testis genes are coordinately expressed and are markers of poor outcome in non‐small cell lung cancer</title></json:item><json:item><author><json:item><name>C Napoletano</name></json:item><json:item><name>F Bellati</name></json:item><json:item><name>E Tarquini</name></json:item><json:item><name>F Tomao</name></json:item><json:item><name>F Taurino</name></json:item><json:item><name>G Spagnoli</name></json:item><json:item><name>A Rughetti</name></json:item><json:item><name>L Muzii</name></json:item><json:item><name>M Nuti</name></json:item><json:item><name>P Benedetti Panici</name></json:item></author><host><volume>198</volume><pages><first>99</first></pages><issue>1</issue><author></author><title>Am J Obstet Gynecol</title></host><title>MAGE‐A and NY‐ESO‐1 expression in cervical cancer: prognostic factors and effects of chemotherapy</title></json:item><json:item><author><json:item><name>S Svobodova</name></json:item><json:item><name>J Browning</name></json:item><json:item><name>D MacGregor</name></json:item><json:item><name>G Pollara</name></json:item><json:item><name>RA Scolyer</name></json:item><json:item><name>R Murali</name></json:item><json:item><name>JF Thompson</name></json:item><json:item><name>S Deb</name></json:item><json:item><name>A Azad</name></json:item><json:item><name>ID Davis</name></json:item></author><host><volume>47</volume><pages><last>469</last><first>460</first></pages><issue>3</issue><author></author><title>Eur J Cancer</title></host><title>Cancer‐testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate</title></json:item><json:item><author><json:item><name>EF Velazquez</name></json:item><json:item><name>AA Jungbluth</name></json:item><json:item><name>M Yancovitz</name></json:item><json:item><name>S Gnjatic</name></json:item><json:item><name>S Adams</name></json:item><json:item><name>D O'Neill</name></json:item><json:item><name>K Zavilevich</name></json:item><json:item><name>T Albukh</name></json:item><json:item><name>P Christos</name></json:item><json:item><name>M Mazumdar</name></json:item></author><host><volume>7</volume><pages><first>11</first></pages><author></author><title>Cancer Immun</title></host><title>Expression of the Cancer/Testis antigen NY‐ESO‐1 in primary and metastatic malignant melanoma (MM)‐correlation with prognostic factors</title></json:item><json:item><author><json:item><name>T Suyama</name></json:item><json:item><name>T Shiraishi</name></json:item><json:item><name>Y Zeng</name></json:item><json:item><name>W Yu</name></json:item><json:item><name>N Parekh</name></json:item><json:item><name>RL Vessella</name></json:item><json:item><name>J Luo</name></json:item><json:item><name>RH Getzenberg</name></json:item><json:item><name>P Kulkarni</name></json:item></author><host><volume>70</volume><pages><last>1787</last><first>1778</first></pages><issue>16</issue><author></author><title>Prostate</title></host><title>Expression of Cancer/Testis antigens in prostate cancer is associated with disease progression</title></json:item><json:item><author><json:item><name>P Kulkarni</name></json:item><json:item><name>T Shiraishi</name></json:item><json:item><name>K Rajagopalan</name></json:item><json:item><name>R Kim</name></json:item><json:item><name>SM Mooney</name></json:item><json:item><name>RH Getzenberg</name></json:item></author><host><volume>9</volume><pages><last>396</last><first>386</first></pages><issue>7</issue><author></author><title>Nat Rev Urol</title></host><title>Cancer/Testis antigens and urological malignancies</title></json:item><json:item><author><json:item><name>T Shiraishi</name></json:item><json:item><name>RH Getzenberg</name></json:item><json:item><name>P Kulkarni</name></json:item></author><host><volume>14</volume><pages><last>404</last><first>400</first></pages><issue>3</issue><author></author><title>Asian J Androl</title></host><title>Cancer/Testis antigens: Novel tools for discerning aggressive and non‐aggressive prostate cancer</title></json:item><json:item><author><json:item><name>JB Axelsen</name></json:item><json:item><name>J Lotem</name></json:item><json:item><name>L Sachs</name></json:item><json:item><name>E Domany</name></json:item></author><host><volume>104</volume><pages><last>13127</last><first>13122</first></pages><issue>32</issue><author></author><title>Proc Natl Acad Sci USA</title></host><title>Genes overexpressed in different human solid cancers exhibit different tissue‐specific expression profiles</title></json:item><json:item><author><json:item><name>T Shiraishi</name></json:item><json:item><name>N Terada</name></json:item><json:item><name>Y Zeng</name></json:item><json:item><name>T Suyama</name></json:item><json:item><name>J Luo</name></json:item><json:item><name>B Trock</name></json:item><json:item><name>P Kulkarni</name></json:item><json:item><name>RH Getzenberg</name></json:item></author><host><volume>9</volume><pages><first>153</first></pages><author></author><title>J Transl Med</title></host><title>Cancer/Testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy</title></json:item><json:item><author><json:item><name>F Chalmel</name></json:item><json:item><name>AD Rolland</name></json:item><json:item><name>C Niederhauser‐Wiederkehr</name></json:item><json:item><name>SS Chung</name></json:item><json:item><name>P Demougin</name></json:item><json:item><name>A Gattiker</name></json:item><json:item><name>J Moore</name></json:item><json:item><name>JJ Patard</name></json:item><json:item><name>DJ Wolgemuth</name></json:item><json:item><name>B Jegou</name></json:item></author><host><volume>104</volume><pages><last>8351</last><first>8346</first></pages><issue>20</issue><author></author><title>Proc Natl Acad Sci USA</title></host><title>The conserved transcriptome in human and rodent male gametogenesis</title></json:item><json:item><author><json:item><name>T Barrett</name></json:item><json:item><name>DB Troup</name></json:item><json:item><name>SE Wilhite</name></json:item><json:item><name>P Ledoux</name></json:item><json:item><name>C Evangelista</name></json:item><json:item><name>IF Kim</name></json:item><json:item><name>M Tomashevsky</name></json:item><json:item><name>KA Marshall</name></json:item><json:item><name>KH Phillippy</name></json:item><json:item><name>PM Sherman</name></json:item></author><host><volume>39</volume><pages><last>1010</last><first>1005</first></pages><issue>database issue</issue><author></author><title>Nucleic Acids Res</title></host><title>NCBI GEO archive for functional genomics data sets—10 years on</title></json:item><json:item><author><json:item><name>H Parkinson</name></json:item><json:item><name>U Sarkans</name></json:item><json:item><name>N Kolesnikov</name></json:item><json:item><name>N Abeygunawardena</name></json:item><json:item><name>T Burdett</name></json:item><json:item><name>M Dylag</name></json:item><json:item><name>I Emam</name></json:item><json:item><name>A Farne</name></json:item><json:item><name>E Hastings</name></json:item><json:item><name>E Holloway</name></json:item></author><host><volume>39</volume><pages><last>1004</last><first>1002</first></pages><issue>database issue</issue><author></author><title>Nucleic Acids Res</title></host><title>ArrayExpress update—An archive of microarray and high‐throughput sequencing‐based functional genomics experiments</title></json:item><json:item><author><json:item><name>AC Chung</name></json:item><json:item><name>AJ Cooney</name></json:item></author><host><volume>33</volume><pages><last>1146</last><first>1141</first></pages><issue>12</issue><author></author><title>Int J Biochem Cell Biol</title></host><title>Germ cell nuclear factor</title></json:item><json:item><author><json:item><name>AC Chung</name></json:item><json:item><name>X Xu</name></json:item><json:item><name>KA Niederreither</name></json:item><json:item><name>AJ Cooney</name></json:item></author><host><volume>293</volume><pages><last>24</last><first>13</first></pages><issue>1</issue><author></author><title>Dev Biol</title></host><title>Loss of orphan nuclear receptor GCNF function disrupts forebrain development and the establishment of the isthmic organizer</title></json:item><json:item><author><json:item><name>GC Hummelke</name></json:item><json:item><name>AJ Cooney</name></json:item></author><host><volume>68</volume><pages><last>407</last><first>394</first></pages><issue>4</issue><author></author><title>Mol Reprod Dev</title></host><title>Reciprocal regulation of the mouse protamine genes by the orphan nuclear receptor germ cell nuclear factor and CREMtau</title></json:item><json:item><author><json:item><name>ZJ Lan</name></json:item><json:item><name>P Gu</name></json:item><json:item><name>X Xu</name></json:item><json:item><name>KJ Jackson</name></json:item><json:item><name>FJ DeMayo</name></json:item><json:item><name>BW O'Malley</name></json:item><json:item><name>AJ Cooney</name></json:item></author><host><volume>22</volume><pages><last>4081</last><first>4070</first></pages><issue>16</issue><author></author><title>EMBO J</title></host><title>GCNF‐dependent repression of BMP‐15 and GDF‐9 mediates gamete regulation of female fertility</title></json:item><json:item><author><json:item><name>M Rajkovic</name></json:item><json:item><name>KA Iwen</name></json:item><json:item><name>PJ Hofmann</name></json:item><json:item><name>A Harneit</name></json:item><json:item><name>JM Weitzel</name></json:item></author><host><volume>38</volume><pages><last>2278</last><first>2268</first></pages><issue>7</issue><author></author><title>Nucleic Acids Res</title></host><title>Functional cooperation between CREM and GCNF directs gene expression in haploid male germ cells</title></json:item><json:item><author><json:item><name>S Varambally</name></json:item><json:item><name>J Yu</name></json:item><json:item><name>B Laxman</name></json:item><json:item><name>DR Rhodes</name></json:item><json:item><name>R Mehra</name></json:item><json:item><name>SA Tomlins</name></json:item><json:item><name>RB Shah</name></json:item><json:item><name>U Chandran</name></json:item><json:item><name>FA Monzon</name></json:item><json:item><name>MJ Becich</name></json:item></author><host><volume>8</volume><pages><last>406</last><first>393</first></pages><issue>5</issue><author></author><title>Cancer Cell</title></host><title>Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression</title></json:item><json:item><author><json:item><name>F Chalmel</name></json:item><json:item><name>M Primig</name></json:item></author><host><volume>9</volume><pages><first>86</first></pages><author></author><title>BMC Bioinformatics</title></host><title>The Annotation, Mapping, Expression and Network (AMEN) suite of tools for molecular systems biology</title></json:item><json:item><author><json:item><name>G Fromont</name></json:item><json:item><name>F Rozet</name></json:item><json:item><name>X Cathelineau</name></json:item><json:item><name>A Ouzzane</name></json:item><json:item><name>L Doucet</name></json:item><json:item><name>G Fournier</name></json:item><json:item><name>O Cussenot</name></json:item></author><host><volume>72</volume><pages><last>1365</last><first>1359</first></pages><issue>12</issue><author></author><title>Prostate</title></host><title>BCAR1 expression improves prediction of biochemical reccurence after radical prostatectomy</title></json:item><json:item><author><json:item><name>R Britto</name></json:item><json:item><name>O Sallou</name></json:item><json:item><name>O Collin</name></json:item><json:item><name>G Michaux</name></json:item><json:item><name>M Primig</name></json:item><json:item><name>F Chalmel</name></json:item></author><host><volume>40</volume><pages><last>465</last><first>458</first></pages><issue>web server issue</issue><author></author><title>Nucleic Acids Res</title></host><title>GPSy: A cross‐species gene prioritization system for conserved biological processes–application in male gamete development</title></json:item><json:item><author><json:item><name>AM Adesina</name></json:item><json:item><name>Y Nguyen</name></json:item><json:item><name>P Guanaratne</name></json:item><json:item><name>J Pulliam</name></json:item><json:item><name>D Lopez‐Terrada</name></json:item><json:item><name>J Margolin</name></json:item><json:item><name>M Finegold</name></json:item></author><host><volume>38</volume><pages><last>409</last><first>400</first></pages><issue>3</issue><author></author><title>Hum Pathol</title></host><title>FOXG1 is overexpressed in hepatoblastoma</title></json:item><json:item><author><json:item><name>AM Adesina</name></json:item><json:item><name>Y Nguyen</name></json:item><json:item><name>V Mehta</name></json:item><json:item><name>H Takei</name></json:item><json:item><name>P Stangeby</name></json:item><json:item><name>S Crabtree</name></json:item><json:item><name>M Chintagumpala</name></json:item><json:item><name>MK Gumerlock</name></json:item></author><host><volume>85</volume><pages><last>122</last><first>111</first></pages><issue>2</issue><author></author><title>J Neurooncol</title></host><title>FOXG1 dysregulation is a frequent event in medulloblastoma</title></json:item><json:item><author><json:item><name>DW Chan</name></json:item><json:item><name>VW Liu</name></json:item><json:item><name>RM To</name></json:item><json:item><name>PM Chiu</name></json:item><json:item><name>WY Lee</name></json:item><json:item><name>KM Yao</name></json:item><json:item><name>AN Cheung</name></json:item><json:item><name>HY Ngan</name></json:item></author><host><volume>101</volume><pages><last>1443</last><first>1433</first></pages><issue>8</issue><author></author><title>Br J Cancer</title></host><title>Overexpression of FOXG1 contributes to TGF‐beta resistance through inhibition of p21WAF1/CIP1 expression in ovarian cancer</title></json:item><json:item><author><json:item><name>TH Kim</name></json:item><json:item><name>SW Jo</name></json:item><json:item><name>YS Lee</name></json:item><json:item><name>YJ Kim</name></json:item><json:item><name>SC Lee</name></json:item><json:item><name>WJ Kim</name></json:item><json:item><name>SJ Yun</name></json:item></author><host><volume>24</volume><pages><last>473</last><first>468</first></pages><issue>3</issue><author></author><title>J Korean Med Sci</title></host><title>Forkhead box O‐class 1 and forkhead box G1 as prognostic markers for bladder cancer</title></json:item><json:item><author><json:item><name>AJ Cooney</name></json:item><json:item><name>GC Hummelke</name></json:item><json:item><name>T Herman</name></json:item><json:item><name>F Chen</name></json:item><json:item><name>KJ Jackson</name></json:item></author><host><volume>245</volume><pages><last>100</last><first>94</first></pages><issue>1</issue><author></author><title>Biochem Biophys Res Commun</title></host><title>Germ cell nuclear factor is a response element‐specific repressor of transcription</title></json:item><json:item><author><json:item><name>C Heinzer</name></json:item><json:item><name>U Susens</name></json:item><json:item><name>TP Schmitz</name></json:item><json:item><name>U Borgmeyer</name></json:item></author><host><volume>379</volume><pages><last>359</last><first>349</first></pages><issue>3</issue><author></author><title>Biol Chem</title></host><title>Retinoids induce differential expression and DNA binding of the mouse germ cell nuclear factor in P19 embryonal carcinoma cells</title></json:item><json:item><author><json:item><name>DR Rhodes</name></json:item><json:item><name>S Kalyana‐Sundaram</name></json:item><json:item><name>V Mahavisno</name></json:item><json:item><name>R Varambally</name></json:item><json:item><name>J Yu</name></json:item><json:item><name>BB Briggs</name></json:item><json:item><name>TR Barrette</name></json:item><json:item><name>MJ Anstet</name></json:item><json:item><name>C Kincead‐Beal</name></json:item><json:item><name>P Kulkarni</name></json:item></author><host><volume>9</volume><pages><last>180</last><first>166</first></pages><issue>2</issue><author></author><title>Neoplasia</title></host><title>Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles</title></json:item><json:item><author><json:item><name>CJ Best</name></json:item><json:item><name>JW Gillespie</name></json:item><json:item><name>Y Yi</name></json:item><json:item><name>GV Chandramouli</name></json:item><json:item><name>MA Perlmutter</name></json:item><json:item><name>Y Gathright</name></json:item><json:item><name>HS Erickson</name></json:item><json:item><name>L Georgevich</name></json:item><json:item><name>MA Tangrea</name></json:item><json:item><name>PH Duray</name></json:item></author><host><volume>11</volume><pages><last>6834</last><first>6823</first></pages><issue>19 Pt 1</issue><author></author><title>Clin Cancer Res</title></host><title>Molecular alterations in primary prostate cancer after androgen ablation therapy</title></json:item><json:item><author><json:item><name>J Kononen</name></json:item><json:item><name>L Bubendorf</name></json:item><json:item><name>A Kallioniemi</name></json:item><json:item><name>M Barlund</name></json:item><json:item><name>P Schraml</name></json:item><json:item><name>S Leighton</name></json:item><json:item><name>J Torhorst</name></json:item><json:item><name>MJ Mihatsch</name></json:item><json:item><name>G Sauter</name></json:item><json:item><name>OP Kallioniemi</name></json:item></author><host><volume>4</volume><pages><last>847</last><first>844</first></pages><issue>7</issue><author></author><title>Nat Med</title></host><title>Tissue microarrays for high‐throughput molecular profiling of tumor specimens</title></json:item><json:item><author><json:item><name>DJ Brennan</name></json:item><json:item><name>C Kelly</name></json:item><json:item><name>E Rexhepaj</name></json:item><json:item><name>PA Dervan</name></json:item><json:item><name>MJ Duffy</name></json:item><json:item><name>WM Gallagher</name></json:item></author><host><volume>4</volume><pages><last>134</last><first>121</first></pages><issue>3</issue><author></author><title>Cancer Genomics Proteomics</title></host><title>Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer</title></json:item><json:item><author><json:item><name>HA Smith</name></json:item><json:item><name>RJ Cronk</name></json:item><json:item><name>JM Lang</name></json:item><json:item><name>DG McNeel</name></json:item></author><host><volume>71</volume><pages><last>6795</last><first>6785</first></pages><issue>21</issue><author></author><title>Cancer Res</title></host><title>Expression and immunotherapeutic targeting of the SSX family of cancer‐testis antigens in prostate cancer</title></json:item><json:item><author><json:item><name>L von Boehmer</name></json:item><json:item><name>L Keller</name></json:item><json:item><name>A Mortezavi</name></json:item><json:item><name>M Provenzano</name></json:item><json:item><name>G Sais</name></json:item><json:item><name>T Hermanns</name></json:item><json:item><name>T Sulser</name></json:item><json:item><name>AA Jungbluth</name></json:item><json:item><name>LJ Old</name></json:item><json:item><name>G Kristiansen</name></json:item></author><host><volume>6</volume><pages><first>21366</first></pages><issue>7</issue><author></author><title>PLoS ONE</title></host><title>MAGE‐C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer</title></json:item><json:item><author><json:item><name>T Hirose</name></json:item><json:item><name>DA O'Brien</name></json:item><json:item><name>AM Jetten</name></json:item></author><host><volume>152</volume><pages><last>251</last><first>247</first></pages><issue>2</issue><author></author><title>Gene</title></host><title>RTR: A new member of the nuclear receptor superfamily that is highly expressed in murine testis</title></json:item><json:item><author><json:item><name>D Katz</name></json:item><json:item><name>C Niederberger</name></json:item><json:item><name>GR Slaughter</name></json:item><json:item><name>AJ Cooney</name></json:item></author><host><volume>138</volume><pages><last>4372</last><first>4364</first></pages><issue>10</issue><author></author><title>Endocrinology</title></host><title>Characterization of germ cell‐specific expression of the orphan nuclear receptor, germ cell nuclear factor</title></json:item><json:item><author><json:item><name>YL Zhang</name></json:item><json:item><name>KM Akmal</name></json:item><json:item><name>JK Tsuruta</name></json:item><json:item><name>Q Shang</name></json:item><json:item><name>T Hirose</name></json:item><json:item><name>AM Jetten</name></json:item><json:item><name>KH Kim</name></json:item><json:item><name>DA O'Brien</name></json:item></author><host><volume>50</volume><pages><last>102</last><first>93</first></pages><issue>1</issue><author></author><title>Mol Reprod Dev</title></host><title>Expression of germ cell nuclear factor (GCNF/RTR) during spermatogenesis</title></json:item><json:item><author><json:item><name>U Susens</name></json:item><json:item><name>JB Aguiluz</name></json:item><json:item><name>RM Evans</name></json:item><json:item><name>U Borgmeyer</name></json:item></author><host><volume>19</volume><pages><last>420</last><first>410</first></pages><issue>5</issue><author></author><title>Dev Neurosci</title></host><title>The germ cell nuclear factor mGCNF is expressed in the developing nervous system</title></json:item><json:item><author><json:item><name>ZJ Lan</name></json:item><json:item><name>X Xu</name></json:item><json:item><name>AC Chung</name></json:item><json:item><name>AJ Cooney</name></json:item></author><host><volume>80</volume><pages><last>912</last><first>905</first></pages><issue>5</issue><author></author><title>Biol Reprod</title></host><title>Extra‐germ cell expression of mouse nuclear receptor subfamily 6, group A, member 1 (NR6A1)</title></json:item><json:item><author><json:item><name>F Chalmel</name></json:item><json:item><name>A Lardenois</name></json:item><json:item><name>B Evrard</name></json:item><json:item><name>R Mathieu</name></json:item><json:item><name>C Feig</name></json:item><json:item><name>P Demougin</name></json:item><json:item><name>A Gattiker</name></json:item><json:item><name>W Schulze</name></json:item><json:item><name>B Jegou</name></json:item><json:item><name>C Kirchhoff</name></json:item><json:item><name>M Primig</name></json:item></author><host><volume>27</volume><pages><last>3248</last><first>3233</first></pages><issue>11</issue><author></author><title>Hum Reprod</title></host><title>Global human tissue profiling and protein network analysis reveals distinct levels of transcriptional germline‐specificity and identifies target genes for male infertility</title></json:item><json:item><author><json:item><name>GC Hummelke</name></json:item><json:item><name>ML Meistrich</name></json:item><json:item><name>AJ Cooney</name></json:item></author><host><volume>50</volume><pages><last>405</last><first>396</first></pages><issue>4</issue><author></author><title>Mol Reprod Dev</title></host><title>Mouse protamine genes are candidate targets for the novel orphan nuclear receptor, germ cell nuclear factor</title></json:item><json:item><author><json:item><name>U Borgmeyer</name></json:item></author><host><volume>244</volume><pages><last>127</last><first>120</first></pages><issue>1</issue><author></author><title>Eur J Biochem</title></host><title>Dimeric binding of the mouse germ cell nuclear factor</title></json:item><json:item><author><json:item><name>F Chen</name></json:item><json:item><name>AJ Cooney</name></json:item><json:item><name>Y Wang</name></json:item><json:item><name>SW Law</name></json:item><json:item><name>BW O'Malley</name></json:item></author><host><volume>8</volume><pages><last>1444</last><first>1434</first></pages><issue>10</issue><author></author><title>Mol Endocrinol</title></host><title>Cloning of a novel orphan receptor (GCNF) expressed during germ cell development</title></json:item><json:item><author><json:item><name>H Greschik</name></json:item><json:item><name>R Schule</name></json:item></author><host><volume>76</volume><pages><last>810</last><first>800</first></pages><issue>12</issue><author></author><title>J Mol Med (Berl)</title></host><title>Germ cell nuclear factor: An orphan receptor with unexpected properties</title></json:item><json:item><author><json:item><name>H Greschik</name></json:item><json:item><name>JM Wurtz</name></json:item><json:item><name>P Hublitz</name></json:item><json:item><name>F Kohler</name></json:item><json:item><name>D Moras</name></json:item><json:item><name>R Schule</name></json:item></author><host><volume>19</volume><pages><last>703</last><first>690</first></pages><issue>1</issue><author></author><title>Mol Cell Biol</title></host><title>Characterization of the DNA‐binding and dimerization properties of the nuclear orphan receptor germ cell nuclear factor</title></json:item><json:item><author><json:item><name>ZH Yan</name></json:item><json:item><name>A Medvedev</name></json:item><json:item><name>T Hirose</name></json:item><json:item><name>H Gotoh</name></json:item><json:item><name>AM Jetten</name></json:item></author><host><volume>272</volume><pages><last>10572</last><first>10565</first></pages><issue>16</issue><author></author><title>J Biol Chem</title></host><title>Characterization of the response element and DNA binding properties of the nuclear orphan receptor germ cell nuclear factor/retinoid receptor‐related testis‐associated receptor</title></json:item><json:item><author><json:item><name>UM Bauer</name></json:item><json:item><name>S Schneider‐Hirsch</name></json:item><json:item><name>S Reinhardt</name></json:item><json:item><name>T Pauly</name></json:item><json:item><name>A Maus</name></json:item><json:item><name>F Wang</name></json:item><json:item><name>R Heiermann</name></json:item><json:item><name>M Rentrop</name></json:item><json:item><name>A Maelicke</name></json:item></author><host><volume>249</volume><pages><last>837</last><first>826</first></pages><issue>3</issue><author></author><title>Eur J Biochem</title></host><title>Neuronal cell nuclear factor—A nuclear receptor possibly involved in the control of neurogenesis and neuronal differentiation</title></json:item><json:item><author><json:item><name>G Fuhrmann</name></json:item><json:item><name>AC Chung</name></json:item><json:item><name>KJ Jackson</name></json:item><json:item><name>G Hummelke</name></json:item><json:item><name>A Baniahmad</name></json:item><json:item><name>J Sutter</name></json:item><json:item><name>I Sylvester</name></json:item><json:item><name>HR Scholer</name></json:item><json:item><name>AJ Cooney</name></json:item></author><host><volume>1</volume><pages><last>387</last><first>377</first></pages><issue>3</issue><author></author><title>Dev Cell</title></host><title>Mouse germline restriction of Oct4 expression by germ cell nuclear factor</title></json:item><json:item><author><json:item><name>Z Yan</name></json:item><json:item><name>AM Jetten</name></json:item></author><host><volume>275</volume><pages><last>35085</last><first>35077</first></pages><issue>45</issue><author></author><title>J Biol Chem</title></host><title>Characterization of the repressor function of the nuclear orphan receptor retinoid receptor‐related testis‐associated receptor/germ cell nuclear factor</title></json:item><json:item><author><json:item><name>Z Yan</name></json:item><json:item><name>YS Kim</name></json:item><json:item><name>AM Jetten</name></json:item></author><host><volume>277</volume><pages><last>32388</last><first>32379</first></pages><issue>35</issue><author></author><title>J Biol Chem</title></host><title>RAP80, a novel nuclear protein that interacts with the retinoid‐related testis‐associated receptor</title></json:item><json:item><author><json:item><name>EM Mullen</name></json:item><json:item><name>P Gu</name></json:item><json:item><name>AJ Cooney</name></json:item></author><host><volume>2007</volume><pages><first>61563</first></pages><author></author><title>PPAR Res</title></host><title>Nuclear receptors in regulation of mouse ES cell pluripotency and differentiation</title></json:item><json:item><author><json:item><name>C Zechel</name></json:item></author><host><volume>72</volume><pages><last>5556</last><first>550</first></pages><issue>4</issue><author></author><title>Mol Reprod Dev</title></host><title>The germ cell nuclear factor (GCNF)</title></json:item><json:item><author><json:item><name>H Zhao</name></json:item><json:item><name>Z Li</name></json:item><json:item><name>AJ Cooney</name></json:item><json:item><name>ZJ Lan</name></json:item></author><host><volume>12</volume><pages><last>3405</last><first>3398</first></pages><author></author><title>Front Biosci</title></host><title>Orphan nuclear receptor function in the ovary</title></json:item><json:item><author><json:item><name>Y Sun</name></json:item><json:item><name>J Niu</name></json:item><json:item><name>J Huang</name></json:item></author><host><volume>1</volume><pages><last>162</last><first>148</first></pages><issue>2</issue><author></author><title>Am J Transl Res</title></host><title>Neuroendocrine differentiation in prostate cancer</title></json:item><json:item><author><json:item><name>G Ahlgren</name></json:item><json:item><name>K Pedersen</name></json:item><json:item><name>S Lundberg</name></json:item><json:item><name>G Aus</name></json:item><json:item><name>J Hugosson</name></json:item><json:item><name>PA Abrahamsson</name></json:item></author><host><volume>42</volume><pages><last>279</last><first>274</first></pages><issue>4</issue><author></author><title>Prostate</title></host><title>Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment</title></json:item><json:item><author><json:item><name>T Jiborn</name></json:item><json:item><name>A Bjartell</name></json:item><json:item><name>PA Abrahamsson</name></json:item></author><host><volume>51</volume><pages><last>589</last><first>585</first></pages><issue>4</issue><author></author><title>Urology</title></host><title>Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment</title></json:item><json:item><author><json:item><name>L Puccetti</name></json:item><json:item><name>CT Supuran</name></json:item><json:item><name>PP Fasolo</name></json:item><json:item><name>E Conti</name></json:item><json:item><name>G Sebastiani</name></json:item><json:item><name>S Lacquaniti</name></json:item><json:item><name>R Mandras</name></json:item><json:item><name>MG Milazzo</name></json:item><json:item><name>N Dogliani</name></json:item><json:item><name>P De Giuli</name></json:item></author><host><volume>48</volume><pages><last>221;</last><first>215</first></pages><issue>2</issue><author></author><title>Eur Urol</title></host><title>Skewing towards neuroendocrine phenotype in high grade or high stage androgen‐responsive primary prostate cancer</title></json:item><json:item><author><json:item><name>DM Panchision</name></json:item><json:item><name>RD McKay</name></json:item></author><host><volume>12</volume><pages><last>487</last><first>478</first></pages><issue>4</issue><author></author><title>Curr Opin Genet Dev</title></host><title>The control of neural stem cells by morphogenic signals</title></json:item></refBibs><genre><json:string>article</json:string></genre><host><volume>73</volume><publisherId><json:string>PROS</json:string></publisherId><pages><total>12</total><last>1114</last><first>1103</first></pages><issn><json:string>0270-4137</json:string></issn><issue>10</issue><subject><json:item><value>Original Article</value></json:item></subject><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1097-0045</json:string></eissn><title>The Prostate</title><doi><json:string>10.1002/(ISSN)1097-0045</json:string></doi></host><categories><wos><json:string>science</json:string><json:string>urology & nephrology</json:string><json:string>endocrinology & metabolism</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>oncology & carcinogenesis</json:string></scienceMetrix></categories><publicationDate>2013</publicationDate><copyrightDate>2013</copyrightDate><doi><json:string>10.1002/pros.22659</json:string></doi><id>6636028DAD7073A903B1AA8F93CFB8DD8ED432B5</id><score>0.1869281</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/6636028DAD7073A903B1AA8F93CFB8DD8ED432B5/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/6636028DAD7073A903B1AA8F93CFB8DD8ED432B5/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/6636028DAD7073A903B1AA8F93CFB8DD8ED432B5/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Expression screening of cancer/testis genes in prostate cancer identifies nr6a1 as a novel marker of disease progression and aggressiveness</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Copyright © 2013 Wiley Periodicals, Inc.</p></availability><date>2013</date></publicationStmt><notesStmt><note type="content">*Michael Primig and Frédéric Chalmel contributed equally to this work.</note><note type="content">*The authors declare no potential conflicts of interest.</note><note>ARTP Fellowship</note><note>ARC - No. 7985;</note><note>Inserm Avenir - No. R07216NS;</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Expression screening of cancer/testis genes in prostate cancer identifies nr6a1 as a novel marker of disease progression and aggressiveness</title><author xml:id="author-1"><persName><forename type="first">Romain</forename><surname>Mathieu</surname></persName><affiliation>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes, France</affiliation><affiliation>Département d'Urologie, CHU de Rennes, Rennes, France</affiliation></author><author xml:id="author-2"><persName><forename type="first">Bertrand</forename><surname>Evrard</surname></persName><affiliation>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes, France</affiliation></author><author xml:id="author-3"><persName><forename type="first">Gaëlle</forename><surname>Fromont</surname></persName><affiliation>Département d'Anatomocytopathologie, CHU/Université de Poitiers, Poitiers, France</affiliation><affiliation>Centre d'étude et de Recherche sur les Pathologies Prostatiques, Paris, France</affiliation></author><author xml:id="author-4"><persName><forename type="first">Nathalie</forename><surname>Rioux‐Leclercq</surname></persName><affiliation>Service d'Anatomie et Cytologie Pathologiques, CHU/Université de Rennes, Rennes, France</affiliation></author><author xml:id="author-5"><persName><forename type="first">Julie</forename><surname>Godet</surname></persName><affiliation>Département d'Anatomocytopathologie, CHU/Université de Poitiers, Poitiers, France</affiliation></author><author xml:id="author-6"><persName><forename type="first">Xavier</forename><surname>Cathelineau</surname></persName><affiliation>Institut Mutualiste Montsouris, Paris, France</affiliation></author><author xml:id="author-7"><persName><forename type="first">François</forename><surname>Guillé</surname></persName><affiliation>Département d'Urologie, CHU de Rennes, Rennes, France</affiliation><affiliation>Centre Régional de Lutte Contre le Cancer Eugène Marquis, Rennes, France</affiliation></author><author xml:id="author-8"><persName><forename type="first">Michael</forename><surname>Primig</surname></persName><affiliation>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes, France</affiliation></author><author xml:id="author-9"><persName><forename type="first">Frédéric</forename><surname>Chalmel</surname></persName><affiliation>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes, France</affiliation><affiliation>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes F‐35042, France.</affiliation></author></analytic><monogr><title level="j">The Prostate</title><title level="j" type="abbrev">Prostate</title><idno type="pISSN">0270-4137</idno><idno type="eISSN">1097-0045</idno><idno type="DOI">10.1002/(ISSN)1097-0045</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2013-07"></date><biblScope unit="volume">73</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1103">1103</biblScope><biblScope unit="page" to="1114">1114</biblScope></imprint></monogr><idno type="istex">6636028DAD7073A903B1AA8F93CFB8DD8ED432B5</idno><idno type="DOI">10.1002/pros.22659</idno><idno type="ArticleID">PROS22659</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2013</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Cancer/Testis (CT) genes are expressed in male gonads, repressed in most healthy somatic tissues and de‐repressed in various somatic malignancies including prostate cancers (PCa). Because of their specific expression signature and their associations with tumor aggressiveness and poor outcomes, CT genes are considered to be useful biomarkers and they are also targets for the development of new anti‐cancer immunotherapies. The aim of this study was to identify novel CT genes associated with hormone‐sensitive prostate cancer (HSPC), and castration‐resistant prostate cancer (CRPC).</p></abstract><abstract><p>To identify novel CT genes we screened genes for which transcripts were detected by RNA profiling specifically in normal testis and in either HSPC or CRPC as compared to normal prostate and 44 other healthy tissues using GeneChips. The expression and clinicopathological significance of a promising candidate—NR6A1—was examined in HSPC, CRPC, and metastatic site samples using tissue microarrays.</p></abstract><abstract><p>We report the identification of 98 genes detected in CRPC, HSPC and testicular samples but not in the normal controls. Among them, cellular levels of NR6A1 were found to be higher in HSPC compared to normal prostate and further increased in metastatic lesions and CRPC. Furthermore, increased NR6A1 immunoreactivity was significantly associated with a high Gleason score, advanced pT stage and cancer cell proliferation.</p></abstract><abstract><p>Our results show that cellular levels of NR6A1 are correlated with disease progression in PCa. We suggest that this essential orphan nuclear receptor is a potential therapeutic target as well as a biomarker of PCa aggressiveness. Prostate 73: 1103–1114, 2013. © 2013 Wiley Periodicals, Inc.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>Cancer/Testis genes</term></item><item><term>castration‐resistant prostate cancer</term></item><item><term>biomarker</term></item><item><term>NR6A1</term></item><item><term>nuclear receptor</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>Original Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2012-11-23">Received</change><change when="2013-02-10">Registration</change><change when="2013-07">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/6636028DAD7073A903B1AA8F93CFB8DD8ED432B5/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1097-0045</doi><issn type="print">0270-4137</issn><issn type="electronic">1097-0045</issn><idGroup><id type="product" value="PROS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="PROSTATE, THE">The Prostate</title><title type="short">Prostate</title></titleGroup></publicationMeta><publicationMeta level="part" position="100"><doi origin="wiley" registered="yes">10.1002/pros.v73.10</doi><numberingGroup><numbering type="journalVolume" number="73">73</numbering><numbering type="journalIssue">10</numbering></numberingGroup><coverDate startDate="2013-07">July 2013</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="90" status="forIssue"><doi origin="wiley" registered="yes">10.1002/pros.22659</doi><idGroup><id type="unit" value="PROS22659"></id></idGroup><countGroup><count type="pageTotal" number="12"></count></countGroup><titleGroup><title type="articleCategory">Original Article</title><title type="tocHeading1">Original Articles</title></titleGroup><copyright ownership="publisher">Copyright © 2013 Wiley Periodicals, Inc.</copyright><eventGroup><event type="manuscriptReceived" date="2012-11-23"></event><event type="manuscriptAccepted" date="2013-02-10"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.2.2 mode:FullText" date="2013-05-30"></event><event type="publishedOnlineEarlyUnpaginated" date="2013-03-26"></event><event type="firstOnline" date="2013-03-26"></event><event type="publishedOnlineFinalForm" date="2013-05-30"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-10"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.6.4 mode:FullText" date="2015-10-02"></event></eventGroup><numberingGroup><numbering type="pageFirst">1103</numbering><numbering type="pageLast">1114</numbering></numberingGroup><correspondenceTo>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes F‐35042, France.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:PROS.PROS22659.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="3"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="72"></count><count type="wordTotal" number="7950"></count></countGroup><titleGroup><title type="main" xml:lang="en">Expression screening of cancer/testis genes in prostate cancer identifies nr6a1 as a novel marker of disease progression and aggressiveness<link href="#fn1"></link><link href="#fn2"></link></title><title type="short" xml:lang="en">Expression Screening of Cancer/Testis Genes</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Romain</givenNames><familyName>Mathieu</familyName></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Bertrand</givenNames><familyName>Evrard</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3 #af4"><personName><givenNames>Gaëlle</givenNames><familyName>Fromont</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Nathalie</givenNames><familyName>Rioux‐Leclercq</familyName></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Julie</givenNames><familyName>Godet</familyName></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Xavier</givenNames><familyName>Cathelineau</familyName></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af2 #af7"><personName><givenNames>François</givenNames><familyName>Guillé</familyName></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Michael</givenNames><familyName>Primig</familyName></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Frédéric</givenNames><familyName>Chalmel</familyName></personName><contactDetails><email>frederic.chalmel@inserm.fr</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes, France</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>Département d'Urologie, CHU de Rennes, Rennes, France</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="FR" type="organization"><unparsedAffiliation>Département d'Anatomocytopathologie, CHU/Université de Poitiers, Poitiers, France</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="FR" type="organization"><unparsedAffiliation>Centre d'étude et de Recherche sur les Pathologies Prostatiques, Paris, France</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="FR" type="organization"><unparsedAffiliation>Service d'Anatomie et Cytologie Pathologiques, CHU/Université de Rennes, Rennes, France</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="FR" type="organization"><unparsedAffiliation>Institut Mutualiste Montsouris, Paris, France</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="FR" type="organization"><unparsedAffiliation>Centre Régional de Lutte Contre le Cancer Eugène Marquis, Rennes, France</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Cancer/Testis genes</keyword><keyword xml:id="kwd2">castration‐resistant prostate cancer</keyword><keyword xml:id="kwd3">biomarker</keyword><keyword xml:id="kwd4">NR6A1</keyword><keyword xml:id="kwd5">nuclear receptor</keyword></keywordGroup><fundingInfo><fundingAgency>ARTP Fellowship</fundingAgency></fundingInfo><fundingInfo><fundingAgency>ARC</fundingAgency><fundingNumber>7985</fundingNumber></fundingInfo><fundingInfo><fundingAgency>Inserm Avenir</fundingAgency><fundingNumber>R07216NS</fundingNumber></fundingInfo><supportingInformation><p> Additional Supporting Information may be found in the online version of this article. </p><supportingInfoItem><mediaResource alt="supporting information" href="urn-x:wiley:02704137:media:pros22659:pros_22659_sm_SuppFile1"></mediaResource><caption>Supplemental File 1</caption></supportingInfoItem><supportingInfoItem><mediaResource alt="supporting information" href="urn-x:wiley:02704137:media:pros22659:pros_22659_sm_SuppFile2"></mediaResource><caption>Supplemental File 2</caption></supportingInfoItem><supportingInfoItem><mediaResource alt="supporting information" href="urn-x:wiley:02704137:media:pros22659:pros_22659_sm_SuppFile3"></mediaResource><caption>Supplemental File 3</caption></supportingInfoItem></supportingInformation><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><section xml:id="abs1-1"><title type="main">BACKGROUND</title><p>Cancer/Testis (CT) genes are expressed in male gonads, repressed in most healthy somatic tissues and de‐repressed in various somatic malignancies including prostate cancers (PCa). Because of their specific expression signature and their associations with tumor aggressiveness and poor outcomes, CT genes are considered to be useful biomarkers and they are also targets for the development of new anti‐cancer immunotherapies. The aim of this study was to identify novel CT genes associated with hormone‐sensitive prostate cancer (HSPC), and castration‐resistant prostate cancer (CRPC).</p></section><section xml:id="abs1-2"><title type="main">METHODS</title><p>To identify novel CT genes we screened genes for which transcripts were detected by RNA profiling specifically in normal testis and in either HSPC or CRPC as compared to normal prostate and 44 other healthy tissues using GeneChips. The expression and clinicopathological significance of a promising candidate—NR6A1—was examined in HSPC, CRPC, and metastatic site samples using tissue microarrays.</p></section><section xml:id="abs1-3"><title type="main">RESULTS</title><p>We report the identification of 98 genes detected in CRPC, HSPC and testicular samples but not in the normal controls. Among them, cellular levels of NR6A1 were found to be higher in HSPC compared to normal prostate and further increased in metastatic lesions and CRPC. Furthermore, increased NR6A1 immunoreactivity was significantly associated with a high Gleason score, advanced pT stage and cancer cell proliferation.</p></section><section xml:id="abs1-4"><title type="main">CONCLUSIONS</title><p>Our results show that cellular levels of NR6A1 are correlated with disease progression in PCa. We suggest that this essential orphan nuclear receptor is a potential therapeutic target as well as a biomarker of PCa aggressiveness. Prostate 73: 1103–1114, 2013. © 2013 Wiley Periodicals, Inc.</p></section></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Michael Primig and Frédéric Chalmel contributed equally to this work.</p></note><note xml:id="fn2"><p>The authors declare no potential conflicts of interest.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Expression screening of cancer/testis genes in prostate cancer identifies nr6a1 as a novel marker of disease progression and aggressiveness</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Expression Screening of Cancer/Testis Genes</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Expression screening of cancer/testis genes in prostate cancer identifies nr6a1 as a novel marker of disease progression and aggressiveness</title></titleInfo><name type="personal"><namePart type="given">Romain</namePart><namePart type="family">Mathieu</namePart><affiliation>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes, France</affiliation><affiliation>Département d'Urologie, CHU de Rennes, Rennes, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Bertrand</namePart><namePart type="family">Evrard</namePart><affiliation>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gaëlle</namePart><namePart type="family">Fromont</namePart><affiliation>Département d'Anatomocytopathologie, CHU/Université de Poitiers, Poitiers, France</affiliation><affiliation>Centre d'étude et de Recherche sur les Pathologies Prostatiques, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Nathalie</namePart><namePart type="family">Rioux‐Leclercq</namePart><affiliation>Service d'Anatomie et Cytologie Pathologiques, CHU/Université de Rennes, Rennes, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Julie</namePart><namePart type="family">Godet</namePart><affiliation>Département d'Anatomocytopathologie, CHU/Université de Poitiers, Poitiers, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Xavier</namePart><namePart type="family">Cathelineau</namePart><affiliation>Institut Mutualiste Montsouris, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">François</namePart><namePart type="family">Guillé</namePart><affiliation>Département d'Urologie, CHU de Rennes, Rennes, France</affiliation><affiliation>Centre Régional de Lutte Contre le Cancer Eugène Marquis, Rennes, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michael</namePart><namePart type="family">Primig</namePart><affiliation>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Frédéric</namePart><namePart type="family">Chalmel</namePart><affiliation>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes, France</affiliation><affiliation>Inserm Unité 1085‐Irset, Université de Rennes 1, Rennes F‐35042, France.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2013-07</dateIssued><dateCaptured encoding="w3cdtf">2012-11-23</dateCaptured><dateValid encoding="w3cdtf">2013-02-10</dateValid><copyrightDate encoding="w3cdtf">2013</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">3</extent><extent unit="tables">2</extent><extent unit="references">72</extent><extent unit="words">7950</extent></physicalDescription><abstract>Cancer/Testis (CT) genes are expressed in male gonads, repressed in most healthy somatic tissues and de‐repressed in various somatic malignancies including prostate cancers (PCa). Because of their specific expression signature and their associations with tumor aggressiveness and poor outcomes, CT genes are considered to be useful biomarkers and they are also targets for the development of new anti‐cancer immunotherapies. The aim of this study was to identify novel CT genes associated with hormone‐sensitive prostate cancer (HSPC), and castration‐resistant prostate cancer (CRPC).</abstract><abstract>To identify novel CT genes we screened genes for which transcripts were detected by RNA profiling specifically in normal testis and in either HSPC or CRPC as compared to normal prostate and 44 other healthy tissues using GeneChips. The expression and clinicopathological significance of a promising candidate—NR6A1—was examined in HSPC, CRPC, and metastatic site samples using tissue microarrays.</abstract><abstract>We report the identification of 98 genes detected in CRPC, HSPC and testicular samples but not in the normal controls. Among them, cellular levels of NR6A1 were found to be higher in HSPC compared to normal prostate and further increased in metastatic lesions and CRPC. Furthermore, increased NR6A1 immunoreactivity was significantly associated with a high Gleason score, advanced pT stage and cancer cell proliferation.</abstract><abstract>Our results show that cellular levels of NR6A1 are correlated with disease progression in PCa. We suggest that this essential orphan nuclear receptor is a potential therapeutic target as well as a biomarker of PCa aggressiveness. Prostate 73: 1103–1114, 2013. © 2013 Wiley Periodicals, Inc.</abstract><note type="content">*Michael Primig and Frédéric Chalmel contributed equally to this work.</note><note type="content">*The authors declare no potential conflicts of interest.</note><note type="funding">ARTP Fellowship</note><note type="funding">ARC - No. 7985; </note><note type="funding">Inserm Avenir - No. R07216NS; </note><subject lang="en"><genre>keywords</genre><topic>Cancer/Testis genes</topic><topic>castration‐resistant prostate cancer</topic><topic>biomarker</topic><topic>NR6A1</topic><topic>nuclear receptor</topic></subject><relatedItem type="host"><titleInfo><title>The Prostate</title></titleInfo><titleInfo type="abbreviated"><title>Prostate</title></titleInfo><genre type="journal">journal</genre><note type="content"> Additional Supporting Information may be found in the online version of this article.Supporting Info Item: Supplemental File 1 - Supplemental File 2 - Supplemental File 3 - </note><subject><genre>article-category</genre><topic>Original Article</topic></subject><identifier type="ISSN">0270-4137</identifier><identifier type="eISSN">1097-0045</identifier><identifier type="DOI">10.1002/(ISSN)1097-0045</identifier><identifier type="PublisherID">PROS</identifier><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>73</number></detail><detail type="issue"><caption>no.</caption><number>10</number></detail><extent unit="pages"><start>1103</start><end>1114</end><total>12</total></extent></part></relatedItem><identifier type="istex">6636028DAD7073A903B1AA8F93CFB8DD8ED432B5</identifier><identifier type="DOI">10.1002/pros.22659</identifier><identifier type="ArticleID">PROS22659</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2013 Wiley Periodicals, Inc.</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E64 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000E64 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:6636028DAD7073A903B1AA8F93CFB8DD8ED432B5
|texte= Expression screening of cancer/testis genes in prostate cancer identifies nr6a1 as a novel marker of disease progression and aggressiveness
}}
| This area was generated with Dilib version V0.6.29. |  |